Oncopeptides AB (publ)
ONPPF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $31,648 | $35,220 | $8,355 | $118,295 |
| % Growth | -10.1% | 321.5% | -92.9% | – |
| Cost of Goods Sold | $2,663 | -$1,079 | $6 | $53,121 |
| Gross Profit | $28,985 | $36,299 | $8,349 | $65,174 |
| % Margin | 91.6% | 103.1% | 99.9% | 55.1% |
| R&D Expenses | $121,186 | $106,948 | $217,657 | $679,926 |
| G&A Expenses | $60,843 | $68,878 | $84,093 | $175,459 |
| SG&A Expenses | $197,282 | $188,479 | $142,195 | $873,805 |
| Sales & Mktg Exp. | $136,439 | $119,601 | $58,102 | $698,346 |
| Other Operating Expenses | -$5,985 | -$5,681 | $0 | $0 |
| Operating Expenses | $312,483 | $289,746 | $357,699 | $1,486,091 |
| Operating Income | -$283,498 | -$253,447 | -$349,350 | -$1,420,917 |
| % Margin | -895.8% | -719.6% | -4,181.3% | -1,201.2% |
| Other Income/Exp. Net | -$711 | $5,000 | $11,670 | -$455 |
| Pre-Tax Income | -$284,209 | -$248,447 | -$337,680 | -$1,421,372 |
| Tax Expense | $398 | $664 | $271 | $8,946 |
| Net Income | -$284,607 | -$249,111 | -$337,951 | -$1,430,317 |
| % Margin | -899.3% | -707.3% | -4,044.9% | -1,209.1% |
| EPS | -1.87 | -2.76 | -4.11 | -19 |
| % Growth | 32.2% | 32.8% | 78.4% | – |
| EPS Diluted | -1.87 | -2.76 | -4.11 | -19 |
| Weighted Avg Shares Out | 152,590 | 90,389 | 82,320 | 75,292 |
| Weighted Avg Shares Out Dil | 152,590 | 90,389 | 82,320 | 75,292 |
| Supplemental Information | – | – | – | – |
| Interest Income | $8,197 | $8,592 | $2,616 | $492 |
| Interest Expense | $12,658 | $5,785 | $883 | $948 |
| Depreciation & Amortization | $0 | $11,040 | $17,182 | $21,365 |
| EBITDA | -$283,498 | -$231,622 | -$319,636 | -$1,405,430 |
| % Margin | -895.8% | -657.6% | -3,825.7% | -1,188.1% |